Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 10:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 156 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Treatment 0; Saline placebo Clear all
Completed Phase 4 Interventional Results available

Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia

NCT01147341
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Cimzia, Placebo
Drug
Lead sponsor
Michael Schiff, MD
Individual
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 3, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Sanofi H1N1 + TIV - Adults and Elderly

NCT00943878
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine, Inactivated H1N1 Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
805 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 3, 2026, 10:54 AM EDT
Terminated Phase 2 Interventional

Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients

NCT00722098
View directory record Official record
Conditions
Malignant Melanoma Stage IV
Interventions
DC Vaccine & Cyclophosphamide, DC Vaccine & Placebo
Biological
Lead sponsor
Baylor Research Institute
Other
Eligibility
21 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2013 · Synced Oct 3, 2026, 10:54 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Abatacept in Patients With Active Crohn's Disease

NCT00406653
View directory record Official record
Conditions
Crohn's Disease
Interventions
abatacept, placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
37
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Oct 3, 2026, 10:54 AM EDT
Completed Phase 2 Interventional

Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis

NCT01294410
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Placebo, Anti-IP-10 Antibody
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
23
States / cities
La Jolla, California • Santa Monica, California • Wheat Ridge, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Oct 3, 2026, 10:54 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

NCT02326272
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
14
States / cities
Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Oct 3, 2026, 10:54 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Cycled Testosterone Therapy to Improve Physical Function in Frail Nursing Home Residents

NCT02679274
View directory record Official record
Conditions
Aging
Interventions
Placebo, Testosterone
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
60 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Galveston, Texas • Texas City, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 3, 2026, 10:54 AM EDT
Completed Phase 3 Interventional Results available

A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04718103
View directory record Official record
Conditions
Asthma
Interventions
GSK3511294, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
41
States / cities
Alabaster, Alabama • Mobile, Alabama • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 3, 2026, 10:54 AM EDT
Completed Phase 1 Interventional

Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy

NCT04985760
View directory record Official record
Conditions
HIV Infections
Interventions
Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant
Biological
Lead sponsor
Madhu Chhanda Choudhary
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 3, 2026, 10:54 AM EDT
Completed Phase 3 Interventional Results available

A Study of Abatacept in Patients With Active Ulcerative Colitis

NCT00410410
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
abatacept (ABA), placebo, abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
50
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 3, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B

NCT00764634
View directory record Official record
Conditions
Botulism Vaccine
Interventions
Placebo (USP sterile saline for injection), rBV A/B-40 vaccine
Biological
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
6
States / cities
Miami, Florida • Pembroke Pines, Florida • Lenexa, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2011 · Synced Oct 3, 2026, 10:54 AM EDT
Completed Phase 1Phase 2 Interventional

Zofin (Organicell Flow) for Patients With COVID-19

NCT04384445
View directory record Official record
Conditions
Corona Virus Infection, COVID-19, SARS, Acute Respiratory Distress Syndrome
Interventions
Zofin, Placebo
Biological · Other
Lead sponsor
ZEO ScientifiX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 3, 2026, 10:54 AM EDT
Withdrawn Not applicable Interventional

tDCS in Cervical Dystonia

NCT02180139
View directory record Official record
Conditions
Cervical Dystonia
Interventions
transcranial direct current stimulation
Device
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Oct 3, 2026, 10:54 AM EDT
Terminated Phase 2 Interventional

Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer

NCT00850577
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Paclitaxel, Carboplatin, CT-322, Bevacizumab, Bevacizumab placebo (ie saline solution)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
20
States / cities
Tucson, Arizona • San Diego, California • Orlando, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 3, 2026, 10:54 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Restylane Silk Acne Scar Efficacy Evaluation Study

NCT02955381
View directory record Official record
Conditions
Acne, Acne Scars, AdverseEvent
Interventions
Restylane Silk, 1.0 ml, Saline, 1.0 ml
Device
Lead sponsor
Schweiger Dermatology, PLLC
Industry
Eligibility
22 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 3, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of XT-150 for Facet Joint Osteoarthritis Pain

NCT05196919
View directory record Official record
Conditions
Facet Joint Pain, Back Pain, Inflammation
Interventions
XT-150, Placebo
Biological
Lead sponsor
Xalud Therapeutics, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Napa, California • Santa Monica, California • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 3, 2026, 10:54 AM EDT
Completed Phase 4 Interventional Results available

Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia

NCT02034474
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Tocilizumab, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 59 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 3, 2026, 10:54 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris

NCT01920477
View directory record Official record
Conditions
Pemphigus Vulgaris
Interventions
Ofatumumab, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
7
States / cities
Los Angeles, California • Atlanta, Georgia • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 3, 2026, 10:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

NCT04927585
View directory record Official record
Conditions
HIV Infections
Interventions
env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, GLA-SE adjuvant, Placebo
Biological
Lead sponsor
Worcester HIV Vaccine
Industry
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 3, 2026, 10:54 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps

NCT02134925
View directory record Official record
Conditions
Colorectal Adenoma, Colorectal Carcinoma, Colorectal Conventional Adenoma With Severe Dysplasia, Colorectal Tubulovillous Adenoma
Interventions
Laboratory Biomarker Analysis, MUC1 Peptide-Poly-ICLC Vaccine, Quality-of-Life Assessment, Saline
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
40 Years to 70 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
6
States / cities
Boston, Massachusetts • Rochester, Minnesota • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 3, 2026, 10:54 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Postoperative Pain Control & Relief in Neonates

NCT03677830
View directory record Official record
Conditions
Pain, Postoperative, Premature Infant, Opioid Use
Interventions
Acetaminophen, Saline
Drug
Lead sponsor
St. Louis University
Other
Eligibility
Up to 1 Month
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 3, 2026, 10:54 AM EDT
Completed Phase 4 Interventional Results available

Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines

NCT01391312
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
botulinum toxin Type A, normal saline (placebo)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
East Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Oct 3, 2026, 10:54 AM EDT
Completed Phase 3 Interventional Results available

S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

NCT00445601
View directory record Official record
Conditions
Bladder Cancer
Interventions
gemcitabine hydrochloride, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
70
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 3, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma

NCT00587288
View directory record Official record
Conditions
Asthma
Interventions
Reslizumab, Saline
Biological · Other
Lead sponsor
Ception Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
24
States / cities
Orange, California • Centennial, Colorado • Colorado Springs, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Oct 3, 2026, 10:54 AM EDT